Immune System Diseases
The department focuses on immune‑mediated skin conditions, testing innovative therapies to improve safety and effectiveness for patients.
- Evaluation of novel JAK inhibitors for atopic dermatitis
- Assessment of IL‑4/IL‑13 blockade in pediatric atopic dermatitis
- Long‑term safety profiling of nemolizumab therapy
- Exploring cytokine‑targeted treatments for chronic urticaria
- Investigating immune modulation in cutaneous lupus erythematosus
With 51 active trials and 15 investigators, Klinika Ambroziak in Warsaw is a key hub for advancing immune‑related dermatology research in Europe.
Skin and Connective Tissue Diseases
Research aims to develop and compare treatments for prevalent skin disorders, seeking better control of disease activity and quality of life.
- Comparative efficacy of biologics for moderate‑to‑severe plaque psoriasis
- Testing new oral agents for hidradenitis suppurativa
- Investigating repigmentation strategies in vitiligo
- Hair‑regrowth outcomes in alopecia areata
- Evaluating topical innovations for acne vulgaris
The clinic’s dermatology unit conducts extensive trials across these conditions, contributing to therapeutic advances for patients throughout Poland.
Immune System Phenomena
Studies explore underlying immune mechanisms, biomarkers, and symptom pathways to refine diagnostic tools and personalize therapy.
- Biomarker analysis of itch severity in prurigo nodularis
- Pharmacodynamic profiling of JAK‑STAT inhibition in atopic dermatitis
- Assessment of skin microbiome changes with tralokinumab treatment
- Immune‑cell infiltration studies in cutaneous lupus erythematosus
- Evaluation of cytokine signatures in chronic inducible urticaria
These investigations support the development of targeted approaches, aligning with the site’s commitment to cutting‑edge immunodermatology.
Dermatology Clinical Research
The overall program integrates multiple therapeutic areas to test novel drugs, assess long‑term safety, and improve patient‑reported outcomes.
- Phase‑III trials comparing new biologics with established standards for moderate‑to‑severe atopic dermatitis
- Placebo‑controlled studies of topical agents for acne vulgaris
- Long‑duration safety extensions for therapies targeting hidradenitis suppurativa
- Exploratory trials of oral compounds in vitiligo management
- Head‑to‑head evaluations of systemic options for chronic spontaneous urticaria
Conducted at Klinika Ambroziak, the site’s multidisciplinary team advances dermatologic care through robust clinical investigation.
